Related Experiment Video
Updated: Dec 16, 2025
05:10
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
12.5K
Targeting the medulloblastoma: a molecular-based approach
Sabino Luzzi1, Alice Giotta Lucifero2, Ilaria Brambilla3
1Neurosurgery Unit, Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Neurosurgery Unit, Department of Surgical Sciences, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. sabino.luzzi@unipv.it.
Acta Bio-Medica : Atenei Parmensis
|July 2, 2020
Summary
New medulloblastoma treatments focus on molecular subtypes and immunotherapies. Overcoming challenges like the blood-brain barrier is key to improving survival and reducing side effects.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- Standard medulloblastoma therapies show limited success, necessitating novel treatment strategies.
- Molecular characterization and risk stratification are crucial for developing personalized therapeutic approaches.
Purpose of the Study:
- To provide an overview of novel treatment strategies for medulloblastoma.
- To highlight current clinical trials and challenges in translating tailored approaches into practice.
Main Methods:
- Literature search on PubMed/MEDLINE and ClinicalTrials.gov for molecular classification, clinical trials, and new treatment strategies.
- Selection of English-language articles published within the last five years.
Main Results:
- Analysis of 58 articles and 51 clinical trials (Phase I, II, I/II).
- Target and adoptive immunotherapies represent key strategies for both newly diagnosed and recurrent medulloblastoma.
Conclusions:
- Ongoing efforts focus on refining targeted therapies and immunotherapies, including engineered T-cells and oncoviruses.
- Key translational challenges include the blood-brain barrier, chemoresistance, tumor microenvironment, and cancer stem cells, which must be addressed to improve outcomes.
